Učitavanje...
Impact of Radiochemotherapy on Immune Cell Subtypes in High-Grade Glioma Patients
Glioblastoma is a dreadful disease with very poor prognosis, median overall survival being <2 years despite standard-of-care treatment. This has led to the development of alternative strategies, among which immunotherapy is being actively tested. In particular, many clinical trials of therapeutic...
Spremljeno u:
| Izdano u: | Front Oncol |
|---|---|
| Glavni autori: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7034105/ https://ncbi.nlm.nih.gov/pubmed/32117743 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00089 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|